BMNDF.US Biomind Labs Inc.
- Market cap
- USD 16.7M
- P/E
- -
- P/B
- 183.79x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BMNDF.US undervalued?
Graham numberThe Graham number of Biomind Labs Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biomind Labs Inc. fundamental analysis
No fundamental analysis for Biomind Labs Inc. yet.
Biomind Labs Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biomind Labs Inc.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's dis…
Full company profileBiomind Labs Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biomind Labs Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 324K | 959K | 404K | 20.9K | 2.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 324K | 959K | 404K | 20.9K | 2.59K | -28.1K | -42.5K | -15.4K | -8.49K | -2.27K | - |
| Operating Income | -834K | -1.56M | -1.59M | -280K | -190K | -3.40M | -2.89M | -976K | -396K | -861K | -1.47M |
| EBITDA | -866K | -1.55M | -1.12M | -192K | 36.5M | -3.40M | -2.89M | -1.03M | -396K | -859K | -1.47M |
| Net Income | -615K | -3.75M | -1.14M | -364K | -190K | -4.33M | -2.99M | -1.21M | -260K | -865K | -1.57M |
| EPS | 0.00 | -0.02 | -0.12 | -0.04 | -0.02 | -0.06 | -0.04 | -0.02 | 0.00 | -0.01 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 17.2M | 17.3M | 1.57M | 371K | 87.7K | 2.53M | 89.1K | 74.2K | 41.2K | 36.00 | 35.00 |
| Total Liabilities | 207K | 204K | 259K | 52.2K | 61.8K | 335K | 337K | 1.51M | 1.34M | 1.74M | 1.90M |
| Shareholders' Equity | 15.1M | 15.5M | 1.31M | 319K | 25.9K | 2.19M | -248K | -1.42M | -1.30M | -1.74M | -1.90M |
| Cash & Short-term Investments | 1.17M | 5.99M | 1.56M | 334K | 82.0K | 2.27M | 26.2K | 24.3K | 147.00 | 36.00 | 35.00 |
| Total Debt | - | - | - | - | - | 45.3K | 8.16K | 736K | 671K | 728K | 829K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.12M | -1.39M | -810K | -608K | -150K | -2.12M | -2.15M | -766K | -354K | -68.7K | -288K |
| Capital Expenditure | 11.2K | 0.00 | 0.00 | 0.00 | 44.6K | 44.6K | 0.00 | 0.26 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.13M | -1.39M | -810K | -608K | -150K | -2.17M | -2.15M | -766K | -354K | -68.7K | -288K |
| Ratios | |||||||||||
| ROE | -4.1% | -24.1% | -86.5% | -114.3% | -734.7% | -197.5% | - | - | - | - | - |
| ROA | -3.6% | -21.6% | -72.2% | -98.2% | -216.7% | -171.4% | -3,352.6% | -1,636.1% | -632.8% | -2,403,605.6% | -4,486,548.6% |
| Net Profit Margin | -189.8% | -390.6% | -281.1% | -1,739.4% | -7,341.6% | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | - | 0.02x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biomind Labs Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 108K | 0.01 | - |
| 2019 | USD 741K | 0.08 | - |
| 2018 | USD 12.8M | 1.39 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:1 on Oct 31, 2018.
Who owns Biomind Labs Inc.
- Insiders 36.31%
- Institutions 0.00%
- Public & others 63.69%
- Shares outstanding 77.6M
- Free float 49.4M
Biomind Labs Inc. company profile
- Company name
- Biomind Labs Inc.
- Ticker
- BMNDF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 515 ? 701 W. Georgia Street, Vancouver, BC, Canada, V7Y 1C6
- Website
- biomindlabs.com
About Biomind Labs Inc.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's disease; BMND06 is in Phase I clinical trial for treatment of morbid obesity; and BMDO9 is in Phase I clinical trial for treatment of Parkinson's disease. It is also developing preclinical drug candidates, including BMND02 for the treatment of fibromyalgia; BMND03 for the treatment of addictive disorders; BMND05 to treat chronic pain; and BMND07 for the treatment of major depressive disorder. The company is headquartered in Vancouver, Canada.
Biomind Labs Inc. management
4- Mr. Alejandro AntalichCEO & Director · born 1974
- Mr. Oscar Alejandro León Bentancor CPACFO & Director · born 1959
- Ms. Paola Diaz Dellavalle Ph.D.Chief Scientific Officer
- Mr. Juan PresaChief Legal Officer · born 1991